FIBROGEN INC (FGEN) Stock Price, Quote, News and Overview
NASDAQ:FGEN - Nasdaq - US31572Q8087 - Common Stock - Currency: USD
FGEN Quote, Performance and Key Statistics
0.7059
-0.07 (-8.61%)
The current stock price of FGEN is 0.7059 USD. In the past month the price increased by 39.45%. In the past year, price decreased by -61.21%.
FGEN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FGEN
Company Profile
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 486 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. The company also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Company Info
FIBROGEN INC
350 Bay Street, Suite 100 #6009
San Francisco CALIFORNIA 94158 US
CEO: Enrique Conterno
Employees: 486
Company Website: https://www.fibrogen.com/
Investor Relations: https://investor.fibrogen.com
Phone: 14159781200
FIBROGEN INC / FGEN FAQ
What is the stock price of FIBROGEN INC today?
The current stock price of FGEN is 0.7059 USD. The price decreased by -8.61% in the last trading session.
What is the ticker symbol for FIBROGEN INC stock?
The exchange symbol of FIBROGEN INC is FGEN and it is listed on the Nasdaq exchange.
On which exchange is FGEN stock listed?
FGEN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FIBROGEN INC stock?
8 analysts have analysed FGEN and the average price target is 10.2 USD. This implies a price increase of 1344.96% is expected in the next year compared to the current price of 0.7059. Check the FIBROGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FIBROGEN INC worth?
FIBROGEN INC (FGEN) has a market capitalization of 71.13M USD. This makes FGEN a Micro Cap stock.
How many employees does FIBROGEN INC have?
FIBROGEN INC (FGEN) currently has 486 employees.
What are the support and resistance levels for FIBROGEN INC (FGEN) stock?
FIBROGEN INC (FGEN) has a support level at 0.52. Check the full technical report for a detailed analysis of FGEN support and resistance levels.
Is FIBROGEN INC (FGEN) expected to grow?
The Revenue of FIBROGEN INC (FGEN) is expected to grow by 7.68% in the next year. Check the estimates tab for more information on the FGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FIBROGEN INC (FGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FGEN, evaluating the profitability, health, valuation and growth aspects
- FIBROGEN INC (FGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FIBROGEN INC (FGEN) Sales and EPS estimates to see what analysts future expectations are.
- FIBROGEN INC (FGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FIBROGEN INC (FGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- FIBROGEN INC (FGEN) Stock Chart to make your own analysis
- FIBROGEN INC (FGEN) Latest news and press-releases to stay up to date.
Does FIBROGEN INC (FGEN) stock pay dividends?
FGEN does not pay a dividend.
When does FIBROGEN INC (FGEN) report earnings?
FIBROGEN INC (FGEN) will report earnings on 2025-03-03, after the market close.
What is the Price/Earnings (PE) ratio of FIBROGEN INC (FGEN)?
FIBROGEN INC (FGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.23).
What is the Short Interest ratio of FIBROGEN INC (FGEN) stock?
The outstanding short interest for FIBROGEN INC (FGEN) is 2.91% of its float. Check the ownership tab for more information on the FGEN short interest.
FGEN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to FGEN. When comparing the yearly performance of all stocks, FGEN is one of the better performing stocks in the market, outperforming 73.25% of all stocks.
FGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FGEN. Both the profitability and financial health of FGEN have multiple concerns.
FGEN Financial Highlights
Over the last trailing twelve months FGEN reported a non-GAAP Earnings per Share(EPS) of -1.23. The EPS increased by 58.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to FGEN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 70.86% and a revenue growth 7.68% for FGEN